Bio-Rad Laboratories (NYSE:BIO.B) Shares Pass Below 200-Day Moving Average – Time to Sell?

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $289.87 and traded as low as $261.83. Bio-Rad Laboratories shares last traded at $261.83, with a volume of 100 shares traded.

Bio-Rad Laboratories Price Performance

The firm has a 50 day moving average of $302.18 and a 200-day moving average of $289.87. The company has a current ratio of 5.62, a quick ratio of 4.19 and a debt-to-equity ratio of 0.16. The company has a market cap of $7.06 billion, a P/E ratio of 9.38 and a beta of 1.01.

Bio-Rad Laboratories (NYSE:BIO.B) last announced its quarterly earnings data on Thursday, February 12th. The company reported $2.51 earnings per share (EPS) for the quarter. Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The business had revenue of $693.20 million during the quarter.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.